References
- Albersen M, Shindel AW, Mwamukonda KB, Lue TF. The future is today: emerging drugs for the treatment of erectile dysfunction. Expert Opin. Emerg. Drugs15(3), 467–480 (2010).
- Garnier JP. Rebuilding the R & D engine in big pharma. Harvard Bus. Rev.86(5), 68–70, 72–76, 128 (2008).
- Pugsley MK, Authier SA, Curtis MJ. Principles of safety pharmacology. Br. J. Pharmacol.154(7), 1382–1399 (2008).
- DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J. Health Econ.22(2), 151–185 (2003).
- Munos B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov.8(12), 959–968 (2009).
- Gelijns AC, Thier SO. Medical innovation and institutional interdependence: rethinking university–industry connections. JAMA287(1), 72–77 (2002).
Websites
- BBC News Business, 1 February 2011. Pfizer to close UK research site. www.bbc.co.uk/news/business-12335801
- International Union of Basic and Clinical Pharmacology (IUPHAR). www.iuphar.org
- British Pharmacology Society (BPS). www.bps.ac.uk/view/index.html
- Safety Pharmacology Society (SPS). http://safetypharmacology.org
- International Conference on Harmonization (ICH). www.ich.org
- Health and Environmental Sciences Institute (ILSI). www.hesiglobal.org
- Cardiac Safety Research Consortium (CSRC). https://cardiac-safety.org
- Bionow. 5 July 2010. AstaZeneca strikes deal with MRC Technologies. www.bionow.co.uk/news/astrazenecastrikesdealwithmrctechnology.aspx
- Higher Education Funding Council for England. Research Excellence Framework. www.hefce.ac.uk/research/ref